What are the indications, dosing regimen, administration procedure, monitoring, and contraindications for intravenous ferric carboxymaltose in adults with iron‑deficiency anemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Intravenous Ferric Carboxymaltose (FCM): Clinical Administration Guide

Indications

Ferric carboxymaltose should be considered first-line intravenous iron therapy for adults with iron-deficiency anemia when oral iron has failed, is not tolerated, or in specific clinical scenarios requiring rapid iron repletion. 1, 2

Primary Indications:

  • Chronic heart failure with reduced ejection fraction (LVEF <40%) and iron deficiency (ferritin <100 μg/L, or ferritin 100–299 μg/L with TSAT <20%) 1
  • Intolerance to oral iron due to gastrointestinal side effects (occurring in up to 60% of patients with chronic heart failure) 1
  • Inadequate response to oral iron after adequate trial 1, 2
  • Inflammatory bowel disease (where hepcidin activation impairs oral iron absorption) 2
  • Severe anemia (hemoglobin <10 g/dL) requiring rapid correction 2
  • Heavy uterine bleeding, postpartum iron deficiency, chronic kidney disease, or perioperative anemia 2, 3

Dosing Regimen

The total iron dose should be calculated based on body weight and hemoglobin level—not ferritin or TSAT—using a simplified weight-based table rather than the Ganzoni formula. 1, 2

Weight- and Hemoglobin-Based Dosing Table:

Body Weight (kg) Hemoglobin (g/dL) Total FCM Dose Suggested Regimen
<70 <10 1,500 mg 750 mg × 2 doses ≥7 days apart [2]
≥70 <10 2,000 mg 1,000 mg Day 1 + 1,000 mg Week 6 [2]
≥70 10–14 1,500 mg 1,000 mg Day 1 + 500 mg Week 6 [2]
Any weight 14–15 500 mg Single 500 mg dose [2]

Key Dosing Rules:

  • Maximum single dose: 1,000 mg iron per administration 1, 2
  • Maximum weekly dose: 1,000 mg iron 1, 2
  • If total calculated dose exceeds 1,000 mg, divide into doses separated by at least 7 days 2
  • Do not administer if hemoglobin >15 g/dL 2, 4

Administration Procedure

FCM can be administered as either an undiluted slow IV push over 15 minutes or diluted in 100 mL normal saline infused over 20–30 minutes. 1, 2

Step-by-Step Administration:

  1. Preparation:

    • For IV push: Administer undiluted at 100 mg/min (15 minutes for 1,000 mg dose) 1
    • For IV infusion: Dilute in 100 mL of 0.9% normal saline 2
    • Do not over-dilute, as this affects drug stability 1

  2. Infusion rate:

    • Infuse over 20–30 minutes if diluted 2
    • Administer over 15 minutes if undiluted 1, 2

  3. Monitoring during infusion:

    • Ensure proper IV line placement to avoid extravasation and skin staining 2
    • Have resuscitation equipment immediately available 4

  4. Post-infusion observation:

    • Mandatory 30-minute observation period after each injection to monitor for hypersensitivity reactions 1, 2, 4
    • Monitor vital signs during and after infusion 2

Monitoring and Follow-Up

Iron parameters should not be evaluated within 4 weeks of FCM administration, as circulating iron interferes with assays and ferritin levels are falsely elevated during this period. 2

Monitoring Timeline:

  • 1–2 weeks post-infusion: Hemoglobin should begin to increase 2
  • 4–8 weeks post-infusion:
    • Hemoglobin should increase by 1–2 g/dL 2
    • Check CBC and iron parameters (ferritin, TSAT) 2
  • 3 months post-infusion: Re-evaluate iron status to determine need for maintenance therapy 1, 2

Maintenance Dosing:

  • If ferritin <100 μg/L or ferritin 100–300 μg/L with TSAT <20%, administer 500 mg FCM at 12,24, and 36 weeks 2

Special Monitoring for Repeat Infusions:

  • Check serum phosphate before repeat treatment if administered within 3 months of last dose 2, 4
  • Hypophosphatemia occurs in 47–75% of patients receiving repeat FCM courses 2
  • Most cases are biochemically moderate (0.32–0.64 mmol/L) and asymptomatic, resolving without intervention 2

Contraindications

Absolute contraindications to FCM include hypersensitivity to FCM or its excipients, known serious hypersensitivity to other parenteral iron products, anemia not attributed to iron deficiency, evidence of iron overload, and hemoglobin >15 g/dL. 1, 2, 4

Absolute Contraindications:

  • Hypersensitivity to ferric carboxymaltose or any excipients 1, 2
  • Known serious hypersensitivity to other parenteral iron products 1, 2
  • Anemia not caused by iron deficiency 1, 2
  • Evidence of iron overload or disturbances in iron utilization 2
  • Hemoglobin >15 g/dL 2, 4

Relative Contraindications (Use with Caution):

  • Active bacteremia: Stop FCM treatment in patients with ongoing bacteremia 1, 2
  • Acute or chronic infection (chronic infection alone is not absolute if risk/benefit favors treatment) 2
  • Known drug allergies, especially severe asthma, eczema, or atopic allergies 2
  • Patients requiring repeat infusions within 3 months (risk of hypophosphatemia) 2, 4

Important Safety Considerations

Hypersensitivity Reactions:

  • Serious life-threatening allergic reactions can occur, though the risk is low (≥0.1% to <1.0%) 2, 4
  • Symptoms include: dyspnea, wheezing, hypotension, chest pain, loss of consciousness, swelling, fast heartbeat, cold/clammy skin, blue extremities, itching, rash, hives 4
  • FCM has a lower risk of anaphylaxis than iron dextran, with no reported cases of true anaphylaxis to date 1, 2
  • Resuscitation facilities must be available during administration 1, 4

Hypophosphatemia:

  • Treatment-emergent hypophosphatemia is the most significant laboratory abnormality 2, 5
  • Incidence: 58% with FCM vs. 4% with iron derisomaltose and 1% with iron sucrose 2
  • Can lead to softening of bones and fractures, especially with repeat infusions 4
  • Monitor serum phosphate if repeat treatment needed within 3 months 2, 4

Other Common Adverse Effects:

  • Nausea, high blood pressure, flushing, injection-site reactions, skin redness, dizziness 4
  • Headache, vomiting (in children) 4
  • Most adverse events are mild to moderate in severity 6, 5

Clinical Advantages Over Alternatives

FCM offers significant practical advantages over other IV iron formulations, including high single-dose capacity (1,000 mg vs. 200 mg for iron sucrose), shorter infusion time (15 minutes vs. 4–6 hours for iron dextran), and fewer clinic visits (1–2 vs. 4–7 for iron sucrose). 1, 2

Comparative Benefits:

  • Rapid repletion: Single 1,000 mg infusion over 15 minutes 1, 2
  • Fewer visits: Typically 1–2 infusions vs. 4–7 for iron sucrose 2
  • Lower anaphylaxis risk: No reported anaphylaxis cases vs. 0.6–0.7% with iron dextran 1, 2
  • No test dose required (unlike iron dextran) 1, 2
  • Proven cardiovascular benefit: First IV iron formulation associated with fewer cardiovascular events and hospitalizations in heart failure patients 2

Cost Considerations:

  • Higher acquisition cost (£217.50 per gram) vs. iron sucrose (£70.80) or iron dextran (£79.70) 1
  • Potential overall cost savings due to fewer clinic visits and lower costs for other items 2, 5

Common Pitfalls to Avoid

  1. Do not recheck iron parameters within 4 weeks of FCM administration—ferritin is falsely elevated 2
  2. Do not administer during active bacteremia—stop treatment until infection resolves 1, 2
  3. Do not exceed 1,000 mg per week—risk of adverse effects increases 1, 2
  4. Do not give if hemoglobin >15 g/dL—contraindicated 2, 4
  5. Do not skip the 30-minute post-infusion observation—required for safety monitoring 1, 2, 4
  6. Do not forget to check phosphate before repeat treatment within 3 months 2, 4
  7. Do not use oral iron as first-line in heart failure—the IRONOUT HF trial showed oral iron does not improve exercise capacity or symptoms 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Guideline

Administration of Ferric Carboxymaltose

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the adverse effects of rapid administration of Ferric Carboxymaltose (Intravenous Iron)
What is the recommended treatment protocol for iron deficiency anemia using Ferric carboxymaltose (intravenous iron replacement therapy)?
Can I administer iron carboxymaltose (inj FCM) to an anemic patient with fever?
What is the recommended dose of Ferinject (ferric carboxymaltose) for treating iron deficiency anemia in adults and adolescents over 14 years?
What is the treatment for a patient with anemia and low ferritin (iron) levels?
Is it safe for a healthy adult without hypercholesterolemia, cardiovascular disease, diabetes, or other metabolic disorders to eat three boiled eggs daily?
What is the emergent management of suspected testicular torsion in an adolescent male with sudden severe unilateral scrotal pain, a high‑riding testis, absent cremasteric reflex, and possible nausea or vomiting?
Create an Epic dot phrase for an 80‑year‑old patient with an acute hip fracture and chronic systolic heart failure on a dobutamine infusion who is hemodynamically stable.
In a patient with atopic dermatitis whose eczema is well‑controlled and skin barrier intact, is it safe to use a facial vitamin C (L‑ascorbic acid) serum and what benefits does it offer?
Is the use of Fleet enema (sodium phosphate rectal solution) safe during pregnancy, particularly in the first trimester?
Is a pregnancy at 37 weeks gestational age considered full term?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question